Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer

REFERENCES

• Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–594.
   PubMed Web of Science ®Google Scholar
• Kris MG, Natale RB, Herbst RS, : Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003;290:2149–2158.
   PubMed Web of Science ®Google Scholar
• Han SW, Kim TY, Hwang PG, : Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2005;23:2493–2501.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chang A: Molecular predictors of EGFR-TKI sensitivity in advanced non-small cell lung cancer. Int J Med Sci. 2008;5:209–217.
   PubMedGoogle Scholar
• Chang A, Parikh P, Thongprasert S, : Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol. 2006;1:847–855.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, : Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, : Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–2139.
   PubMed Web of Science ®Google Scholar
• Tsao MS, Sakurada A, Cutz JC, : Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133–144.
   PubMed Web of Science ®Google Scholar
• Takano T, Ohe Y, Sakamoto H, : Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23:6829–6837.
   PubMed Web of Science ®Google Scholar
• Shigematsu H, Lin L, Takahashi T, : Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–346.
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, : Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003;21:2237–2246.
   PubMed Web of Science ®Google Scholar
• Miller VA, Kris MG, Shah N, : Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004;22:1103–1109.
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhong WZ, Li LY, : Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2007;2: 430–439.
   PubMedGoogle Scholar
• Mu XL, Li LY, Zhang XT, : Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer. Clin Cancer Res. 2005;11:4289–4294.
   PubMed Web of Science ®Google Scholar
• Endoh H, Ishibashi Y, Yamaki E, : Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer. 2009;63:241–246.
   PubMed Web of Science ®Google Scholar
• Levkowitz G, Waterman H, Ettenberg SA, : Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell. 1999;4:1029–1040.
   PubMed Web of Science ®Google Scholar
• Mosesson Y, Shtiegman K, Katz M, : Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem. 2003;278:21323–21326.
   PubMed Web of Science ®Google Scholar
• Chen YR, Fu YN, Lin CH, : Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants. Oncogene. 2006;25:1205–1215.
   PubMed Web of Science ®Google Scholar
• Han W, Zhang T, Yu H, Foulke JG, Tang CK: Hypophosphorylation of residue Y1045 leads to defective downregulation of EGFRvIII. Cancer Biol Ther. 2006;5:1361–1368.
   PubMed Web of Science ®Google Scholar
• VanMeter AJ, Rodriguez AS, Bowman ED, : Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics. 2008;7:1902–1924.
   PubMed Web of Science ®Google Scholar
• Okabe T, Okamoto I, Tamura K, : Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. Cancer Res. 2007;67:2046–2053.
   PubMed Web of Science ®Google Scholar
• Turner BC, Krajewski S, Krajewska M, : BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. J Clin Oncol. 2001;19:992–1000.
   PubMed Web of Science ®Google Scholar
• Rakha EA, Abd El Rehim D, Pinder SE, Lewis SA, Ellis IO: E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance. Histopathology. 2005;46:685–693.
   PubMed Web of Science ®Google Scholar
• Morita S, Okamoto I, Kobayashi K, : Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2009;15:4493–4498.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Martins RG, Spigel D, : First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008;26: 2442–2449.
   PubMed Web of Science ®Google Scholar
• He C, Liu M, Zhou C, : Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small cell lung cancer. Int J Cancer. 2009;125:2393–2399.
   PubMed Web of Science ®Google Scholar
• Shih JY, Gow CH, Yu CJ, : Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer. Int J Cancer. 2006;118:963–969.
   PubMed Web of Science ®Google Scholar
• Yu J, Kane S, Wu J, : Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer. Clin Cancer Res. 2009;15:3023–3028.
   PubMed Web of Science ®Google Scholar
• Sordella R, Bell DW, Haber DA, Settleman J.: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004;305:1163–1167.
   PubMed Web of Science ®Google Scholar
• Furukawa M, Nagatomo I, Kumagai T, : Gefitinib-sensitive EGFR lacking residues 746–750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis. DNA Cell Biol. 2007;26:178–185.
   PubMed Web of Science ®Google Scholar
• Emery IF, Battelli C, Auclair PL, Carrier K, Hayes DM: Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study. BMC Cancer. 2009;9:333.
   PubMed Web of Science ®Google Scholar
• Hijiya N, Miyawaki M, Kawahara K, : Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma. Hum Pathol. 2008;39:316–323.
   PubMed Web of Science ®Google Scholar